Patients tested and type of sequencing. Of the total cohort of 65 patients, 38 had samples tested by WES and 59 had samples tested by RNA-Seq. (A) Forty-six CP patients treated with first-line TKIs who were all sequenced at diagnosis. Twenty of the 46 were also sequenced at BC. (B) Nineteen patients selected for sequencing on the basis of available samples at BC. Five of these patients also had samples available for sequencing at diagnosis: 2 patients diagnosed in accelerated phase (AP), 2 patients who received no TKI therapy, and 1 patient treated with a second-line TKI.